Study of the change in the density of tacrolimus in pregnancy and after delivery in CTD patients and blood concentration of mother's body and the childre
Not Applicable
- Conditions
- Conective tissue disease
- Registration Number
- JPRN-UMIN000017009
- Lead Sponsor
- Osaka medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
non
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method we measure the blood concentration (dosage 12 hours later trough value) of the tacrolimus hydrate at the the time of early, middle,latter pregnancy. We gather umbilical cord blood (umbilical cord artery) at the time of placenta delivery and measure blood concentration of tacrolimus. After consent was obtained, we gather the blood of some children (from three months to six months after birth) and measure blood concentration (dosage 12 hours later) of tacrolimus. For a patient nursing, we measure the density of tacrolimus in mother's milk (the dosage ago dosage three hours later dosage 12 hours later). we measure the blood concentration (dosage 12 hours later) of the tacrolimus hydrate by periodical drawing blood.
- Secondary Outcome Measures
Name Time Method